在动脉样硬化中,内皮脂代谢的新兴调节者
Jason S Irei1, Kai Hirayama, William A Boisvert
1Center for Cardiovascular Research, John A. Burns School of Medicine, University of Hawaii, Honolulu, Hawaii, USA.
Current opinion in lipidology
|February 28, 2026
概括
升高的棕酸会破坏内皮细胞的功能,影响心血管健康. 理解内皮脂代谢对于开发新的动脉样硬化治疗方法至关重要.
科学领域:
- 心血管研究研究心血管研究
- 细胞生物学 细胞生物学
- 代谢研究研究 代谢研究
背景情况:
- 尽管有效的高脂血和高血压疗法,心血管疾病 (CVD) 的风险仍然很高.
- 内皮细胞 (ECs) 在动脉样硬化心血管疾病的发展和进展中发挥着关键作用.
- 目前的研究重点是内皮脂代谢,以了解和减轻心血管疾病风险.
研究的目的:
- 审查关于内皮脂代谢的当前研究.
- 为了强调内皮脂代谢在动脉样硬化中的作用.
- 更新关于内皮功能障碍的机制.
主要方法:
- 关于内皮脂代谢的最近研究的文献综述.
- 对将脂质代谢与内皮功能联系起来的分子机制的分析.
- 检查棕酸和胆固醇在内皮平衡中的作用.
主要成果:
- 升高的棕酸 (PA) 通过影响酸异酶M2 (PKM2) 活性,对内皮细胞产生负面影响.
- PA对于内皮纤维化和细胞健康至关重要,但其调节失调是有害的.
- 内皮胆固醇代谢和血动力学力量是内皮平衡的关键调节者;它们的干扰导致功能障碍和脂质积累.
结论:
- 动脉样硬化是一种复杂的疾病,涉及多种细胞类型和功能障碍.
- 在了解内皮脂代谢方面取得了重大进展.
- 需要进一步的研究来确定治疗目标,以减少心血管疾病的风险.
相关概念视频
Atherosclerosis I: Introduction
1.6K
Atherosclerosis is a progressive disorder characterized by the buildup of plaques on the arterial inner wall, causing them to narrow and harden over time. These plaques comprise lipids, calcium, blood components, carbohydrates, and fibrous tissue. The process primarily affects the intima of large and medium-sized arteries, reducing blood flow in any artery.Etiology and risk factorsThe cause of atherosclerosis is multifactorial, involving a complex interplay among endothelial injury, lipid...
1.6K
Regulation of Angiogenesis and Blood Supply
3.8K
Rapidly dividing tumors, embryos, and wounded tissues require more oxygen than usual, lowering the oxygen concentration in the blood. At low oxygen or hypoxic conditions, an oxygen-sensitive transcription factor called the hypoxia-inducible factor 1 or HIF1 is activated. HIF1 is a dimeric protein of alpha (ɑ) and beta (β) subunits. Under optimal oxygen conditions, HIF1β is present in the nucleus while HIF1ɑ remains in the cytosol. HIF1ɑ is hydroxylated by prolyl...
3.8K
Atherosclerosis III: Management
520
Management of atherosclerosis involves an integrated strategy encompassing pharmacological treatment, surgical interventions, lifestyle changes, and nutrition therapy to address the multifactorial nature of the disease.Pharmacological TherapyA cornerstone of atherosclerosis management is the use of pharmacological agents. Statins, such as atorvastatin, are pivotal in inhibiting HMG-CoA reductase, an enzyme that catalyzes an initial step in cholesterol synthesis in the liver. This reduction in...
520
Inflammation
62.9K
Overview
62.9K
Coronary Artery Disease I: Introduction
1.3K
Coronary Artery Disease (CAD): An Overview with Scientific InsightsCoronary Artery Disease (CAD), often referred to as C-A-D, is a prevalent blood vessel disorder classified under the broader category of atherosclerosis. Atherosclerosis is a pathological process characterized by the hardening and narrowing of arteries due to the accumulation of atherosclerotic plaques. These plaques are composed of cholesterol, fatty substances, inflammatory cells, calcium, and fibrin, reducing blood flow to...
1.3K
Coronary Artery Disease II: Pathophysiology
826
Coronary Artery Disease (CAD) originates from a series of events that impair the function of coronary arteries, the blood vessels responsible for delivering oxygen-rich blood to the heart muscle. The pathophysiology of CAD is closely linked to atherosclerosis, a chronic inflammatory and lipid-driven condition affecting the vascular endothelium.1. Endothelial DamageThe process begins with damage to the vascular endothelium, which serves as a protective barrier between the blood and the vessel...
826


